Figure 5.

Sabizabulin inhibits primary tumor growth in the HCI-12 PDX model. (A) The mean increase in tumor volume (mm³) over time on treatment (days on therapy, A) and tumor wet weight (grams, g) (B) at the study endpoint of59 days after treatment with vehicle (3×/week, IP, n = 21 total tumors), paclitaxel (10 mg/kg; 3×/week, IP, n = 22 total tumors), or sabizabulin (20 mg/kg, 3×/week, PO, n = 18 total tumors). (C) The mean ex vivo tumor volume and the percentage increase in body weight for vehicle (n = 11 mice), paclitaxel (n = 11 mice), or sabizabulin (n = 12 mice) relative to body weight at the start of therapy (D); the dashed lines indicate initial body weight (y = 0) with a −10% to +10 % variance over time (days on therapy)(A–C) All pairwise comparisons were made to the vehicle control; **** p < 0.001. (E) Representative images of resected tumors. (F) Representative images of IHC slides stained with cleaved caspase-3 (600× magnification; scale bar 50 μM); yellow arrowheads indicate example apoptotic cells. (G) Scatter plot of % positive area for cleaved-caspase-3. N.S. = not significant.